Montelukast: Nursing Drug Guide, Neuropsychiatric Warning & NCLEX Review

Montelukast sodium is an oral leukotriene receptor antagonist. This guide reflects U.S. FDA prescribing information (DailyMed) for tablets and chewable tablets.

• Brand: Singulair (and multiple generics)
• Tablets: 10 mg film-coated — adults and adolescents ≥15 years
• Chewable tablets: 5 mg (ages 6–14) and 4 mg (ages 2–5); contain aspartame (phenylalanine source)
• Oral granules: 4 mg packet — pediatric use per labeling (bioequivalent to 4 mg chewable in adults)
• Not interchangeable with: inhaled corticosteroids, antihistamines, or rescue bronchodilators — different roles in asthma care

Per U.S. prescribing information, montelukast is indicated for:

• Asthma: Prophylaxis and chronic treatment in adults and pediatric patients ≥12 months (specific age limits vary by formulation)
• Exercise-induced bronchoconstriction (EIB): Prevention in adults and adolescents ≥15 years and children 6–14 years
• Allergic rhinitis: Seasonal allergic rhinitis in adults and children ≥2 years; perennial allergic rhinitis in adults and children ≥6 months (per labeled indications)
• Both asthma and allergic rhinitis: One daily dose in the evening

Nurses support patients with cough, nasal congestion, and exercise-related chest tightness—but montelukast does not replace rescue inhalers or emergency care for severe bronchospasm.

Montelukast selectively antagonizes the cysteinyl leukotriene (CysLT₁) receptor, blocking leukotriene-mediated bronchoconstriction, mucus secretion, vascular permeability, and eosinophil recruitment in asthma and allergic inflammation.

It is a controller therapy—not a bronchodilator. Chronic daily use may improve airway function over time; it does not rapidly reverse acute bronchospasm like a short-acting beta-agonist.

Oral route only. Match tablet or chewable strength to age. Patients who miss a dose should take the next dose at the regular time and not take two doses at once.

Asthma (daily maintenance)

↔On a small screen, swipe or scroll sideways to see the full table.

Exercise-induced bronchoconstriction (EIB)

• Single oral dose at least 2 hours before exercise (10 mg tablet ≥15 years; 5 mg chewable ages 6–14)
• Do not take an additional dose within 24 hours of a previous dose
• Patients already on daily montelukast for asthma should not take an extra dose for EIB
• Daily montelukast for chronic asthma has not been established to prevent acute EIB episodes

Allergic rhinitis

Same age-based doses as above; may be given once daily without regard to food. Time of day may be individualized for rhinitis alone.

Hepatic and renal impairment

No dosage adjustment is recommended in mild-to-moderate hepatic insufficiency or renal insufficiency per U.S. labeling. Pharmacokinetics in severe hepatic impairment or hepatitis have not been evaluated in the reviewed prescribing information.

• Absorption: Rapid; peak plasma concentration in about 3–4 hours for 10 mg tablet in adults (fasted)
• Food: Asthma and EIB trials used evening dosing without mandating fasting; allergic rhinitis dosing may be individualized
• Metabolism: Hepatic via CYP2C8, 2C9, and 3A4
• Elimination: Primarily biliary; not appreciably excreted in urine
• Half-life: Slightly longer in elderly patients; no routine geriatric dose adjustment required per labeling
• Distribution: Animal data show montelukast distributes into the brain; mechanisms of neuropsychiatric events in humans are not well understood per labeling

Answer these before the first dose or at each reconciliation:

• Correct patient, drug, strength (4 mg / 5 mg / 10 mg), formulation (tablet vs chewable), route (oral), and time (evening for asthma)
• Rescue therapy: Short-acting inhaled beta-agonist available and patient can demonstrate use
• Clinical picture: Chronic controller therapy—not acute asthma attack or shortness of breath needing albuterol first
• Neuropsychiatric baseline: Mood, sleep, aggression, anxiety, or suicidal ideation—document and counsel caregivers
• Duplicate dosing: Only one montelukast dose in 24 hours; no extra dose for exercise if already on daily therapy
• Corticosteroid changes: Recent or planned oral prednisone taper—watch for eosinophilia or vasculitic symptoms
• PKU: Chewable tablets contain phenylalanine (0.678 mg per 4 mg tablet; 0.840 mg per 5 mg tablet)
• Hypersensitivity to montelukast or formulation components
• Pregnancy/lactation—discuss risks and benefits; poorly controlled asthma increases perinatal risk
• Home supply reconciliation via medication reconciliation

• Hypersensitivity to montelukast or any component of the formulation (U.S. prescribing information)

Postmarketing reports include hypersensitivity reactions, including anaphylaxis. Not specified in the reviewed prescribing information as a separate absolute contraindication beyond hypersensitivity to the drug itself.

↔On a small screen, swipe or scroll sideways to see the full table.

• Asthma: Administer once daily in the evening with or without food
• Allergic rhinitis: Once daily; timing may be individualized
• EIB: At least 2 hours before exercise; not within 24 hours of another dose
• Chewable tablets: Chew completely before swallowing; PKU warning applies
• Oral granules: May be placed directly in the mouth, dissolved in 5 mL of cold breast milk or formula, or mixed with a spoonful of cold soft food per product instructions in labeling
• Document formulation, strength, and whether dose is maintenance or EIB prophylaxis

• Reduced daytime and nighttime asthma symptoms, rescue inhaler use, and exacerbations over weeks of adherence
• Improved rhinitis symptoms (sneezing, congestion, rhinorrhea) when used for allergic rhinitis
• May decrease exercise-induced symptoms when dosed ≥2 hours pre-exercise per EIB indication—not reliable as sole chronic EIB prevention without rescue plan
• If inadequate control, prescriber adjusts controller regimen (e.g., inhaled corticosteroid)—not by unsupervised extra montelukast doses

• New or worsening neuropsychiatric symptoms—agitation, aggression, anxiety, depression, confusion, insomnia, hallucinations, somnambulism, suicidal thoughts or behavior → discontinue montelukast and contact prescriber immediately per boxed warning
• Acute bronchospasm or asthma attack—use rescue bronchodilator and escalate; montelukast does not replace acute treatment
• Systemic eosinophilia with vasculitic rash, worsening pulmonary symptoms, cardiac symptoms, or neuropathy—especially after oral corticosteroid reduction
• Hypersensitivity/anaphylaxis to montelukast—stop drug and treat per emergency protocol
• Increasing rescue inhaler use, wheezing, nocturnal awakenings, or inability to speak in full sentences—poor asthma control despite therapy

Boxed warning: Serious neuropsychiatric events (variable presentation; may occur with or without prior psychiatric history; may persist after discontinuation in some cases).

↔On a small screen, swipe or scroll sideways to see the full table.

Postmarketing: hypersensitivity (including anaphylaxis), hepatic eosinophilic infiltration, Churg-Strauss syndrome–like features with corticosteroid taper. Report per facility policy.

U.S. prescribing information: no specific information on treatment of overdosage. Reasonable measures include removing unabsorbed material, clinical monitoring, and supportive therapy if required.

Antidote

No specific antidote is described in the reviewed prescribing information. Montelukast is not known to be removed by peritoneal dialysis or hemodialysis.

• Montelukast vs montelukast sodium—same active moiety; verify ordered salt vs base strength on MAR
• Singulair vs similar-sounding agents—read back generic name; do not confuse with antihistamines or inhalers
• 4 mg vs 5 mg vs 10 mg—pediatric chewable strengths are not interchangeable
• Chewable vs film-coated tablet—swallowing a chewable whole or chewing a film-coated tablet are formulation errors
• Controller vs rescue—montelukast stocked near bronchodilators increases wrong-drug risk during emergencies
• Duplicate home Singulair plus inpatient dose—reconcile at admission and discharge

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Asthma control: symptoms, nocturnal awakenings, activity limitation, peak flow or spirometry per care plan
• Rescue inhaler frequency—rising use signals poor control
• Neuropsychiatric status: mood, sleep, behavior, suicidal ideation (patient and caregiver report)
• Rhinitis symptom relief when used for allergies
• Signs of eosinophilic vasculitis during corticosteroid tapers
• Hepatic transaminases if clinically indicated (ALT/AST increases reported in trials)

Document

• Formulation, dose, time, and indication (asthma maintenance, rhinitis, or EIB prophylaxis)
• Boxed-warning counseling and caregiver teach-back
• Rescue inhaler availability and technique verification
• NP symptom assessment at baseline and follow-up
• Hold/discontinuation and prescriber notification when NP events occur

• Montelukast helps prevent symptoms over time—it is not for sudden breathing emergencies; use your rescue inhaler as prescribed
• Take asthma doses in the evening unless your prescriber directs otherwise
• For exercise, take the EIB dose at least 2 hours before activity; do not double doses
• Stop montelukast and call your healthcare provider right away for new mood changes, nightmares, agitation, or thoughts of harming yourself
• Do not stop or change inhaled steroids unless your prescriber tells you
• Bring all asthma and allergy medicines to appointments, including home Singulair bottles
• PKU patients: chewable tablets contain phenylalanine—discuss total daily intake with dietitian/prescriber
• Pregnancy or breastfeeding: discuss risks and benefits with your care team

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for montelukast using a tabbed case (MAR, vitals, history, nursing notes), then priority action, select-all-that-apply cues, trend interpretation, matrix urgency sorting, clinical judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes (neuropsychiatric boxed warning, acute asthma rescue limits, and duplicate-dose prevention).

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.